(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 February 2023 (02.02.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/009438 A1

(51) International Patent Classification:
A61K 31/537 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2022/038188

(22) International Filing Date:
25 July 2022 (25.07.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/225,707 26 July 2021 (26.07.2021) US
63/285,327 02 December 2021 (02.12.2021) US

(71) Applicant: **CELCUITY INC.** [US/US]; 16305 36th Ave N. Ste 100, Minneapolis, MN 55446 (US).

(72) Inventors: **SULLIVAN, Brian, Francis**; 2400 Bantle Farm Road, Medina, MN 55340 (US). **LAING, Lance, Gavin**; 16305 36th Ave N. Ste 100, Minneapolis, MN 55446 (US).

(74) Agent: **REMILLARD, Jane, E.** et al.; Nelson Mullins Riley & Scarborough LLP, One Financial Center, Suite 3500, Boston, MA 02111 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2023/009438 A1

(54) Title: 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA (GEDATOLISIB) AND ITS COMBINATIONS FOR USE IN THE TREATMENT OF CANCER

(57) Abstract: Provided are methods of treating cancer in a human subject. The method includes selecting a subject in need of treatment of cancer; administering to the subject a therapeutically effective amount of gedatolisib at least once a week for a period of three weeks; discontinuing administration of gedatolisib for a period of one week; and resuming administration of gedatolisib at least once a week following the period of discontinuation. The administration for at least a period of three weeks and discontinued administration for at least a period of one week constitutes a cycle, where the cycle is repeated for at least two cycles.